Skip to main content

Milestone 9.B

Initiate synthesis and testing of novel PET ligands and develop and test novel CSF/blood biomarkers for assessment of disease related pathological burdens such as tau, inflammation, synaptic dysfunction. 

Success Criteria

Development and testing of 3-5 novel PET ligands and/or CSF/blood biomarkers for assessment of AD and ADRD pathology.

Time Required

2014 to 2018

Research Implementation Area

Biomarkers

CADRO Category

B. Diagnosis, Assessment and Disease Monitoring

Activities, Funding Initiatives, and Resources

NIH PA-06-017: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…
NIH PA-06-018: Development of PET and SPECT Ligands for Brain Imaging (SBIR [R4…

Funded Research Projects

IADRP – Category B. Diagnosis, Assessment and Disease Monitoring - 1. Fluid Bio…
IADRP – 2. Imaging Biomarkers - b. PET Non-Amyloid Imaging